During the American Heart Association Late-Breaking Scientific Sessions in November 2022, the results of the Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure (STRONG-HF) study were announced. This study focused on optimizing heart failure management after hospitalization for acute heart failure and used the Roche Elecsys NT-proBNP biomarker.
The primary outcomes showed a significant reduction in all-cause death or acute heart failure readmissions at day 180 when the study strategy was implemented.
Hear from Ambarish Pandey, M.D., MSCS, FAHA, associate professor of cardiology, Department of Internal Medicine, UT Southwestern Medical Center, and Robert Christenson, Ph.D., DABCC, FAACC, FACC, professor of pathology and of medical and research technology, University of Maryland School of Medicine, about how a biomarker-supported strategy can enable rapid and safe up-titration of guideline directed medical therapy. They also discuss how this strategy can improve outcomes in heart failure – and what it means for the lab.